Advertisement

Advertisement

Prostate Cancer

PEACE-1: Abiraterone Plus Androgen-Deprivation Therapy and Docetaxel Boosts Survival in Metastatic Castration-Sensitive Prostate Cancer

The addition of abiraterone acetate plus prednisone on top of androgen-deprivation therapy plus docetaxel improved survival in patients with de novo metastatic castration-sensitive prostate cancer vs androgen-deprivation therapy plus docetaxel alone. These results were from the phase III PEACE-1...

Prostate Cancer

Maintained Benefit of Apalutamide Plus Androgen-Deprivation Therapy Shown in Metastatic Castration-Sensitive Prostate Cancer

As reported in the Journal of Clinical Oncology by Kim N. Chi, MD, of BC Cancer and Vancouver Prostate Centre, and colleagues, the final overall survival analysis of the phase III TITAN trial showed significant benefit of apalutamide plus androgen-deprivation therapy vs placebo plus...

Prostate Cancer

Expert Point of View: Mary-Ellen Taplin, MD

Invited discussant of the VISION trial, Mary-Ellen Taplin, MD, of Dana-Farber Cancer Institute, Boston, commented on the study, noting that she was a co-investigator of the trial. “Patients with metastatic castration-resistant prostate cancer have a number of treatment options. There are 10...

Prostate Cancer

VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer

Lutetium-177–PSMA-617 (LuPSMA)—an investigational radiolabeled small molecule—significantly improved radiographic progression-free survival and overall survival when added to the standard of care compared with the standard of care alone for men with metastatic castration-resistant prostate cancer...

Prostate Cancer

First-Line Olaparib Plus Abiraterone Extends Radiographic Progression-Free Survival in Men With Metastatic Castration-Resistant Prostate Cancer

The PARP inhibitor olaparib in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs current standard-of-care abiraterone as a first-line treatment for patients with metastatic castration-resistant...

kidney cancer
bladder cancer
prostate cancer
genomics/genetics
immunotherapy
covid-19

Sumanta K. Pal, MD, on Advances in Genitourinary Cancer Treatment: Expert Perspective

Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses some key research developments in kidney cancer, including data on nivolumab and ipilimumab with or without CBM588 in metastatic renal cell carcinoma; intestinal microbiome associated with the development of grade 3 or 4 adverse events in patients with metastatic disease who have been treated with nivolumab plus ipilimumab and probiotic support; the link between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer; mutations in the androgen receptor gene in patients with prostate cancer receiving novel androgen deprivation treatments; and findings on waning antibody titers in patients who have received COVID-19 vaccinations (Roundup of Abstracts 371, 561, 374, Posters 38 and 48).

Prostate Cancer

Novel Radioligand Therapy Improves Progression-Free and Overall Survival in Patients With Metastatic Prostate Cancer

A novel prostate cancer treatment—actinium Ac-225–PSMA-617 radioligand therapy—has been shown to increase the progression-free and overall survival of patients with metastatic castration-resistant prostate cancer, according to research published by Sathekge et al in the Journal of Nuclear Medicine. ...

Prostate Cancer

Factors Contributing to Racial Disparities in the Use of Prostate MRI in Older Patients With Prostate Cancer

In a study reported in JAMA Oncology, Michael S. Leapman, MD, and colleagues found that sociodemographic factors (like geographic area of residence) as well as manifestations of structural racism (like poverty and racial segregation) accounted for the majority of differences in the use of magnetic...

Prostate Cancer

Expert Point of View: Celestia S. Higano, MD

MAGNITUDE is challenging from a statistical point of view,” said formal discussant Celestia S. Higano, MD, currently Adjunct Professor, Department of Urologic Sciences at the University of British Columbia, Vancouver, Canada, and formerly of Fred Hutchinson Cancer Research Center in Seattle....

prostate cancer

Alicia K. Morgans, MD, MPH, on Prostate Cancer: Profiles of Patients and Their Journeys

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, discusses findings from the largest digital survey conducted in patients with prostate cancer, allowing identification of unmet needs in the patient journey. Preliminary data suggest that lower rates of screening may correlate with higher rates of symptoms at diagnosis and potentially later-stage diagnosis.

Prostate Cancer

Comparison of Multiparametric Ultrasound and Multiparametric MRI for the Diagnosis of Prostate Cancer

In the prospective paired-cohort CADMUS study reported in The Lancet Oncology, Grey et al found that patients at risk of prostate cancer had a similar likelihood of being diagnosed with clinically significant cancer with the use of multiparametric ultrasound vs multiparametric magnetic resonance...

prostate cancer

Kim Nguyen Chi, MD, on Prostate Cancer: New Findings on Niraparib, Abiraterone, and Prednisone

Kim Nguyen Chi, MD, of the University of British Columbia, BC Cancer-Vancouver Center, discusses first phase III results from the MAGNITUDE study, which explored the use of the PARP inhibitor niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without homologous recombination repair gene alterations (Abstract 12).

prostate cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Early Results From the CYPIDES Trial of ODM-208

Karim Fizazi, PhD, MD, of Gustave Roussy and University of Paris-Saclay, discusses results from a first-in-human phase I/II trial, which showed that administering ODM-208—an oral, nonsteroidal inhibitor of the enzyme CYP11A1—to men with metastatic castration-resistant prostate cancer who were pretreated with abiraterone/enzalutamide and taxanes was effective in blocking the production of steroid hormones. It also showed antitumor activity, especially in men with AR mutation–positive cancers.

issues in oncology
bladder cancer
kidney cancer
prostate cancer

Karen E. Knudsen, PhD, MBA, on Addressing Disparities in Genitourinary Cancers

Karen E. Knudsen, PhD, MBA, Chief Executive Officer of the American Cancer Society, discusses ways to address the inequities in genitourinary screening, treatment, and outcomes. Her suggestions focus on increasing awareness of screening, identifying risk factors, the dramatic rise in incidence among Hispanic individuals, and the basis for increased mortality in Black men.

Prostate Cancer

Potential Contribution of Nonmalignant Etiologies to Back Pain in Patients With Metastatic Prostate Cancer

In a single-institution study reported in JCO Oncology Practice, Ruppert et al found that nonmalignant etiologies contribute to back pain in many men with metastatic prostate cancer who experience pain in areas where spinal metastases are known to occur. Study Details The study consisted of...

Bladder Cancer
Kidney Cancer
Prostate Cancer

Minority Enrollment in U.S. Phase II and III Trials in Genitourinary Cancers

In a study reported in the Journal of Clinical Oncology, Owens-Walton et al found that minority populations are underrepresented in phase II and III trials targeting prostate, kidney, and bladder cancers taking place in the United States. Study Details In the analysis, the ClinicalTrials.gov...

prostate cancer

Axel S. Merseburger, MD, on Prostate Cancer: New Data From the PRESIDE Trial on Enzalutamide, Docetaxel, and Prednisolone

Axel S. Merseburger, MD, of the University Hospital Schleswig-Holstein, discusses results from a phase IIIb study of chemotherapy-naive patients with metastatic castration-resistant prostate cancer who have been treated with docetaxel plus prednisolone and experienced disease progression on enzalutamide. The data suggest that continued enzalutamide plus docetaxel improved progression-free survival compared with placebo plus docetaxel (Abstract 15).

prostate cancer

Fred Saad, MD, on Prostate Cancer: Results From the PROpel Trial on Olaparib and Abiraterone

Fred Saad, MD, of the University of Montreal Health Centre, discusses phase III findings demonstrating for the first time the clinical benefits of olaparib plus abiraterone in patients with metastatic castration-resistant prostate cancer, irrespective of their homologous recombination repair mutation status. This regimen led to significantly longer radiographic progression-free survival than placebo plus abiraterone (Abstract 11).

Prostate Cancer

Pain and Quality of Life in the PROfound Trial: Olaparib vs Next-Generation Hormonal Agent in Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations

In an analysis from the phase III PROfound trial reported in The Lancet Oncology, Thiery-Vuillemin et al found that olaparib was associated with better pain outcomes and preservation of health-related quality of life (QOL) vs enzalutamide or abiraterone plus prednisone in a cohort of men with...

Prostate Cancer

Addition of Autologous Dendritic Cell–Based Immunotherapy to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

In a phase III trial (VIABLE) reported in JAMA Oncology, Nicholas J. Vogelzang, MD, and colleagues found that the addition of an autologous dendritic cell–based immunotherapy directed against prostate cancer (DCVAC/PCa) to chemotherapy did not improve overall survival in metastatic...

Prostate Cancer

ARASENS Trial: Addition of Darolutamide to Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

As presented at the 2022 ASCO Genitourinary Cancers Symposium and reported in The New England Journal of Medicine by Smith et al, the phase III ARASENS trial has shown significantly improved overall survival with the addition of darolutamide to androgen-deprivation therapy and docetaxel in men with ...

Prostate Cancer
Genomics/Genetics

New Data Validate Clinical Utility of Genomic Classifier Test to Help Guide Therapy for Men With Intermediate-Risk Prostate Cancer

New data validating the clinical utility of the Decipher prostate genomic classifier for guiding treatment selection in men with intermediate-risk prostate cancer was presented at the 2022 ASCO Genitourinary Cancers Symposium (Abstract 269). Data from the randomized phase III NRG/RTOG 0126 study,...

Prostate Cancer
Genomics/Genetics

PARP Inhibitor Plus Abiraterone Benefits Subgroups of Patients With Metastatic Castration-Resistant Prostate Cancer

The combination of the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib plus abiraterone acetate and prednisone as first-line therapy significantly improved radiographic progression-free survival vs abiraterone and placebo alone in men with metastatic castration-resistant prostate cancer...

Prostate Cancer

Does MRI-Guided Radiotherapy Reduce Treatment-Related Side Effects in Patients With Prostate Cancer?

An interim analysis of an ongoing phase III study indicated that using magnetic resonance imaging (MRI) to guide stereotactic body radiotherapy for patients with prostate cancer reduced side effects associated with the treatment. The findings were presented at the 2022 ASCO Genitourinary Cancers...

Prostate Cancer
Genomics/Genetics

Comprehensive Genetic Risk Score May Predict Risk of Developing Metastatic Prostate Cancer or Death From Prostate Cancer Across Diverse Populations

A new screening tool (called PHS290) that incorporates 290 inherited genetic variants associated with prostate cancer was able to accurately identify people with high vs low lifetime risks of developing metastatic prostate cancer or dying from prostate cancer. These findings of a genetic risk...

Prostate Cancer

Effect of ADT Use and Duration in Combination With Definitive Radiotherapy for Localized Prostate Cancer

In an individual patient-level meta-analysis reported in The Lancet Oncology, Amar U. Kishan, MD, and colleagues found that the addition of androgen-deprivation therapy (ADT) to definitive radiotherapy prolonged metastasis-free and overall survival in patients with localized prostate cancer. Longer ...

Prostate Cancer

New Study Examines Genetic Effects on Genitourinary Toxicity in Patients With Prostate Cancer

Although radiation can be an effective therapy for prostate cancer, about one in six men will experience more frequent or painful urination as a lingering side effect. These disruptive genitourinary toxicities can occur whether the patient receives conventionally fractionated radiotherapy or...

Prostate Cancer

Educational Intervention Increases Knowledge About Prostate Cancer and Intention to Screen Among High-Risk Patients

In a study published by Charnita Zeigler-Johnson, PhD, MPH, and colleagues in the Journal of Racial and Ethnic Health Disparities, gathering men at high risk for developing prostate cancer for discussion about prostate cancer or other health concerns increased their knowledge about prostate cancer...

Prostate Cancer

Role of Expression of ERV RNA in Prostate Cancer

A molecular feature in prostate cancer called endogenous retroviral (ERV) RNA has been found to have prognostic value and also distinguish differences between prostate tumors in men of African and European or Middle Eastern ancestry, according to a study published by Kumar et al in the journal...

Prostate Cancer

Addition of Abiraterone Acetate and Prednisolone With or Without Enzalutamide to ADT in High-Risk Nonmetastatic Prostate Cancer

In a meta-analysis of two STAMPEDE platform phase III trials reported in The Lancet, Gerhardt Attard, PhD, and colleagues found that the addition of abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy (ADT) was associated with improved metastasis-free...

Prostate Cancer

Portable Prostate Cancer Screening Test May Help Reach Underserved Patients

A portable, rapid prostate cancer screening kit could provide early warning to populations with a higher incidence of prostate cancer and may particularly aid those with limited access to health care. The proof-of-concept test, described by Srinivasan et al in Current Research in Biotechnology, is...

Prostate Cancer
Survivorship

Disconnect Between Expectations and Outcomes: Major Factor in Treatment-Related Regret Among Patients With Localized Prostate Cancer

“A disconnect between patient expectations and outcomes” is a major contributor to treatment-related regret among patients with localized prostate cancer, according to a study published in JAMA Oncology.1 The disconnect, “both as it relates to treatment efficacy and adverse effects, appears to...

Prostate Cancer

Health-Related Quality of Life With Enzalutamide vs Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer: ENZAMET Trial

As reported in the Journal of Clinical Oncology by Stockler et al, enzalutamide was associated with worsening in several quality-of-life domains—but not in overall health and quality of life—vs standard of care in the phase III ENZAMET trial evaluating the efficacy of the agent for patients with...

Prostate Cancer

NCCN Guidelines for Prostate Cancer: Panel Clarifies Role of Active Surveillance for Low-Risk Prostate Cancer

In October 2021, the National Comprehensive Cancer Network (NCCN) prostate caycer panel modified its guidelines (NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines®]) for low-risk prostate cancer to remove the word “preferred option” for active surveillance, giving equal weight to...

Prostate Cancer

Effect of Statin Use on Outcomes of PSA Screening for Prostate Cancer

In a Finnish study reported in JAMA Oncology, Vettenranta et al found that statin use did not appear to markedly affect the benefits of prostate-specific antigen (PSA) screening for prostate cancer. As stated by the investigators, “PSA screening for prostate cancer has resulted in a slight...

Prostate Cancer

Does Yoga Improve Quality of Life in Men With Prostate Cancer?

A diagnosis of prostate cancer may translate to approximately a 30% increase in the incidence of depression and anxiety, a fourfold higher risk of heart attack, and a twofold higher risk of suicide. A study published by Kaushik et al in Prostate Cancer and Prostatic Diseases aimed to evaluate the...

Prostate Cancer

Study Examines Treatment-Related Regret Among Men With Localized Prostate Cancer

In a prospective cohort study (CEASAR) reported in JAMA Oncology, Wallis et al found that patient expectations of treatment efficacy and adverse effects were associated with treatment-related regret at 5 years after diagnosis in men with localized prostate cancer. As stated by the investigators,...

Prostate Cancer

Taking Akt-ion Against Prostate Cancer?

Inhibition of the androgen receptor pathway (AR) with novel hormonal therapies such as abiraterone acetate has greatly improved outcomes for patients with metastatic castration-resistant prostate cancer in recent years. However, through numerous mechanisms, tumors ultimately develop resistance...

Prostate Cancer

Addition of Ipatasertib to Abiraterone Plus Prednisolone Improves Radiographic Progression–Free Survival in Metastatic Castration-Resistant Prostate Cancer With PTEN Loss

In a phase III trial (IPATential150) reported in The Lancet, Christopher Sweeney, MD, of Dana-Farber Cancer Institute, and colleagues, found that the addition of the AKT inhibitor ipatasertib to abiraterone and prednisolone produced a significant improvement in radiographic progression-free...

Prostate Cancer

Shorter-Course Radiation Therapy: A New Practice Standard After Prostatectomy?

Hypofractionated radiotherapy to the prostate bed proved to be noninferior to conventionally fractionated radiotherapy after prostatectomy regarding gastrointestinal and genitourinary side effects, according to the results of the phase III NRG Oncology GU003 trial, presented at the 2021 American...

Prostate Cancer

Changes in PSA Screening After 2017 USPSTF Guidance Revision

In a study reported in JAMA Oncology, Michael S. Leapman, MD, and colleagues found that prostate-specific antigen (PSA) screening for prostate cancer has increased since the 2017 publication of the U.S. Preventive Services Task Force (USPSTF) draft guidance endorsing individual decision-making for...

Prostate Cancer

STAMPEDE Trial: Quality of Life With Abiraterone vs Docetaxel in Advanced Hormone-Sensitive Prostate Cancer

In an analysis from the STAMPEDE trial reported in the Journal of Clinical Oncology, Rush et al found that global quality of life was better with abiraterone acetate vs docetaxel, both given with prednisone/prednisolone and standard-of-care androgen-deprivation therapy, in men with locally advanced ...

Prostate Cancer

Use of Genomic Classifier Score May Help to Personalize Therapy for Men With High-Risk Prostate Cancer

A 22-genomic classifier (the Decipher score) was able to predict the course of disease in men with high-risk prostate cancer, according to a patient-level meta-analysis of three randomized clinical trials presented at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 Use of...

Prostate Cancer

No Survival Benefit but Improved Secondary Endpoints With Radiotherapy Plus Androgen Suppression in Intermediate-Risk Prostate Cancer

Both dose-escalated radiation therapy and short-course androgen-deprivation therapy have been shown to improve outcomes in intermediate-risk prostate cancer, but it is not clear whether giving both modalities upfront to newly diagnosed patients is of benefit. The phase III RTOG 0815 study presented ...

prostate cancer

Howard M. Sandler, MD, on Prostate Cancer Highlights: An Expert Perspective

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses whether hypofractionation can be safely employed in the post-prostatectomy setting and the role of short-term hormone therapy in the management of intermediate-risk prostate cancer with radiotherapy.

Prostate Cancer

Racial Disparities in Use of Prostate MRI After Detection of Elevated PSA Levels

In a study published by Abashidze et al in JAMA Network Open, the investigators found that Black men were at least 23.6% less likely than White men to undergo magnetic resonance imaging (MRI) following an elevated prostate-specific antigen (PSA) test result. They also found that Hispanic and Asian...

Prostate Cancer

Studies Find B7-H3 Protein May Be a Target for Prostate Cancer Treatment

The immune checkpoint protein B7-H3 may be a potential new target in treatment-resistant prostate cancers, according to two studies presented recently at the European Society for Medical Oncology (ESMO) Congress 2021. “Virtually every prostate cancer cell expresses some degree of B7-H3, which...

prostate cancer

Amar U. Kishan, MD, on Prostate Cancer: Impact of Androgen-Deprivation Therapy With Radiotherapy

Amar U. Kishan, MD, of the University of California, Los Angeles, discusses findings from a meta-analysis of clinical trials in patients with localized prostate cancer. The phase III results suggest that the use of androgen-deprivation therapy (ADT) or prolonged adjuvant ADT with radiotherapy may benefit patients with localized prostate cancer. Further biomarkers are needed to better personalize treatment intensification (Abstract 8).

prostate cancer

Mark K. Buyyounouski, MD, MS, on Prostate Cancer: Hypofractionated vs Conventional Radiotherapy After Surgery

Mark K. Buyyounouski, MD, MS, of Stanford University, discusses phase III results from the NRG Oncology GU003 trial, which showed that, post-prostatectomy, using fewer—but higher—doses of radiation does not appear to increase long-term side effects or reduce quality of life when compared with conventional radiation treatment (Abstract 3).

prostate cancer

Benjamin Movsas, MD, on Prostate Cancer: Patient-Reported Outcomes on Radiotherapy and Androgen Suppression

Benjamin Movsas, MD, of the Henry Ford Cancer Center, discusses results from the NRG Oncology/RTOG 0815 study, which explored dose-escalated radiotherapy alone or in combination with short-term hormonal therapy for patients with intermediate-risk prostate cancer. In addition to clinical outcomes, Dr. Movsas discusses patient-reported results in the study that may help patients make informed decisions when choosing between these treatment options (Abstract 4).

Advertisement

Advertisement

Advertisement